Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system.

AOD-9604

Growth hormone fragment16 amino acids

CPreclinical
70
Good Credibility
1 cited study | Evidence level C

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) originally developed for obesity treatment. It has been explored as a lipolytic agent in research but has not received FDA approval or GRAS status for any use.

Mechanism of Action

Mimics the lipolytic fragment of growth hormone, stimulating fat breakdown while having no effect on IGF-1 levels or blood glucose. Does not exhibit the growth-promoting effects of full GH.

Benefits

  • Fat reduction without GH-related side effects in animal studies[1]
  • Research exploration in animal models only — no regulatory approval[1]
  • No impact on insulin sensitivity or blood glucose[1]
  • Does not promote tissue growth[1]
Not medical advice - research-reported information only

This content is for informational purposes only and does not constitute medical advice.

AOD-9604 - Dosing in Published Research

Reported routes: Subcutaneous injection, Oral
Phase 2 obesity trial used 1 mg SC daily. Limited clinical data available for dosing guidance.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Limited human trial data[1]
  • Mild headache reported[1]
  • Injection site reactions[1]
  • Uncertain long-term safety profile

Considering peptide research?

AOD-9604 is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.

Get the Provider Checklist

Start with the evidence and provider checklist while routing is offline.

Always consult a professional

Research & Evidence

Compare AOD-9604 With

References

  1. 1.The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.. Endocrinology, 2001. "AOD-9604 reduced fat mass in obese mice via beta(3)-adrenergic receptor mediated lipolysis without affecting blood glucose or IGF-1" [PMID: 11713213]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Research Supplies

Equipment for responsible research-grade peptide handling and administration.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

AOD-9604 FAQ